Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial. (September 2020)

• Record Type: Journal Article
• Authors: Conte, Benedetta; Bruzzone, Marco; Lambertini, Matteo; Poggio, Francesca; Bighin, Claudia; Blondeaux, Eva; De Laurentiis, Michelino; Valle, Enrichetta; Cognetti, Francesco; Nisticò, Cecilia; De Placido, Sabino; Garrone, Ornella; Gamucci, Teresa; Montemurro, Filippo; Puglisi, Fabio; Cardinali, Barbara; Fregatti, Piero; Miglietta, Loredana; Boccardo, Francesco; Ceppi, Marcello; Del Mastro, Lucia
• Is Part Of: European journal of cancer. Volume 136(2020)
• Page Start: 43
• Page End: 51
• Publication Date: 2020-09
• Subjects: Breast cancer -- Dose-dense chemotherapy -- Hormone receptor-positive -- Luminal subtype; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Cancer; Tumors; Electronic journals; Periodicals; Electronic journals; 616.994
• DOI: 10.1016/j.ejca.2020.05.007
• Languages: English
• ISSNs: 0959-8049

Abstract

Abstract: Background: Luminal A-like and luminal B-like subtypes have different sensitivity to (neo)adjuvant chemotherapy, but their role in predicting dose-dense (DD) efficacy in the high-risk setting is unknown. In this exploratory analysis of the Gruppo Italiano Mammella 2 (GIM2) trial, we investigated DD efficacy according to luminal-like subtypes. Methods: Patients with node-positive early breast cancer were randomised to receive either DD or standard-interval (SI) anthracycline-based chemotherapy followed by paclitaxel. In our analysis, luminal A-like cohort was identified as having a Ki67 < 20% and a progesterone receptor (PgR) ≥ 20%; luminal B-like cohort as having a Ki67 ≥ 20% and/or a PgR < 20%. Results: Out of 2003 patients enrolled in the GIM2 trial, 412 had luminal A-like and 638 luminal B-like breast cancer. After a median follow-up of 7.9 years, disease-free survival (DFS) was 80.8% (95% confidence interval [CI] 76.4–84.5) and 70.5% (66.5–74.2) in luminal A-like and luminal B-like cohorts; overall survival (OS) was 91.6% (88.2–94.1) and 85.1% (81.7–87.9), respectively. We found no significant interaction between treatment and luminal subtype (interaction p = 0.603 and 0.535 for DFS and OS, respectively). When DD efficacy was investigated separately in each cohort, luminal-B like cohort appeared to benefit more from the DD schedule both in terms of DFS (unadjusted hazard ratio [HR] 0.72 [95% CI 0.54–0.96]) and OS (unadjusted HR 0.61 [95% CI 0.40–0.94]), compared with the luminal A-like cohort (unadjusted HR for DFS 0.89 [95% CI 0.59–1.33]; unadjusted HR for OS 0.83 [95% CI 0.45–1.54]). Conclusions: No significant interaction between luminal-like subtype and treatment was observed. Patients in the luminal B-like cohort seemed to benefit more from DD schedule. Highlights: Dose-dense chemotherapy improves outcome in hormone receptor-positive breast cancer. Differences in dose-dense effect according to luminal subtype are still unknown. In the Gruppo Italiano Mammella 2 trial, there was no interaction between luminal subtype and treatment. Yet, only the luminal B cohort derived survival benefit from dose-dense schedule. No benefit from dose-dense chemotherapy was observed in the luminal A-like cohort.